Magnetic Resonance Imaging (MRI) and radiological study of Rheumatoid Arthritis treated with Adalimumab and non-biological agents to assess the impact of disease control on MRI manifestations and joint structure preservation.

Not Applicable

• Conditions: Rheumatoid Arthritis; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12612000903886
• Lead Sponsor: Emeritus Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

1.Stable therapy for at least 6 months, non-biological DMARDs with a DAS-28 of < 2.6
2.Stable therapy for at least six months, Adalimumab, DAS-28 < 2.6.
3.Stable therapy for at least six months, Adalimumab, DAS -28 > 3.2
4.Rheumatoid factor or CCP positive at some stage in the course of their disease
5.Capable of undergoing MRI examinations.
6.Capable of understanding the Informed Consent document.
7.Anticipate stable treatment for at least 18 months
8.Reliable to attend for the review

Exclusion Criteria

1.Contra-indications to MRI examination, including but not limited, to metallic brain clips, previous stapedectomy, cardiac pacemaker, profound claustrophobia or inability to lie in the MRI machine in an appropriate position to obtain quality images.
2.Women who are pregnant or breast feeding or planning to become pregnant during the study.
3.Treatment with any investigational therapy within 3 months
4.Not willing to return for required follow-up visits or there is a clear demonstration of likely poor compliance;
5.Any other medical condition (including current infections) that, in the judgment of the Investigator, would prohibit the patient from participating in the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified